Get started
ALNYLAM PHARMACEUTICALS INCALNYLAM PHARMACEUTICALS INCALNYLAM PHARMACEUTICALS INC

ALNYLAM PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

ALNY chart


Full chart

ALNY upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪708.14 B‬MXN
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−51.65MXN
Net income (FY)
‪−7.48 B‬MXN
Revenue (FY)
‪31.05 B‬MXN
Shares float
‪127.23 M‬
Beta (1Y)
0.88

Employees


Employees (FY)
‪2.1 K‬
Change (1Y)
+98 +4.90%
Revenue / Employee (1Y)
‪870.62 K‬MXN
Net income / Employee (1Y)
‪−209.64 K‬MXN

About Alnylam Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Yvonne L. Greenstreet
Headquarters
Cambridge
Website
alnylam.com
Founded
2002
FIGI
BBG00PG3DGY3
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

ALNY news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ALNY highest yielding bonds


ALNY5653584
Alnylam Pharmaceuticals, Inc. 1.0% 15-SEP-2027
Yield to maturity
−4.08%
Maturity date
Sep 15, 2027

Explore more bonds 

Sparks


Curated watchlists where ALNY is featured.

See all sparks 

Frequently Asked Questions


The current price of ALNY is 5,899.69 MXN — it has increased by 17.29% in the past 24 hours. Watch ALNYLAM PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange ALNYLAM PHARMACEUTICALS INC stocks are traded under the ticker ALNY.
We've gathered analysts' opinions on ALNYLAM PHARMACEUTICALS INC future price: according to them, ALNY price has a max estimate of 8,017.64 MXN and a min estimate of 3,607.94 MXN. Watch ALNY chart and read a more detailed ALNYLAM PHARMACEUTICALS INC stock forecast: see what analysts think of ALNYLAM PHARMACEUTICALS INC and suggest that you do with its stocks.
ALNY reached its all-time high on Oct 22, 2024 with the price of 5,899.69 MXN, and its all-time low was 1,355.78 MXN and was reached on Jun 14, 2019. View more price dynamics on ALNY chart.
See other stocks reaching their highest and lowest prices.
ALNY stock is 14.74% volatile and has beta coefficient of 0.88. Track ALNYLAM PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is ALNYLAM PHARMACEUTICALS INC there?
Today ALNYLAM PHARMACEUTICALS INC has the market capitalization of ‪686.01 B‬, it has increased by 2.94% over the last week.
Yes, you can track ALNYLAM PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
ALNYLAM PHARMACEUTICALS INC is going to release the next earnings report on Feb 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ALNY earnings for the last quarter are −17.14 MXN per share, whereas the estimation was −18.06 MXN resulting in a 5.09% surprise. The estimated earnings for the next quarter are −12.84 MXN per share. See more details about ALNYLAM PHARMACEUTICALS INC earnings.
ALNYLAM PHARMACEUTICALS INC revenue for the last quarter amounts to ‪9.87 B‬ MXN, despite the estimated figure of ‪10.50 B‬ MXN. In the next quarter, revenue is expected to reach ‪11.40 B‬ MXN.
ALNY net income for the last quarter is ‪−2.20 B‬ MXN, while the quarter before that showed ‪−309.78 M‬ MXN of net income which accounts for −609.65% change. Track more ALNYLAM PHARMACEUTICALS INC financial stats to get the full picture.
No, ALNY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 2, 2024, the company has ‪2.10 K‬ employees. See our rating of the largest employees — is ALNYLAM PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ALNYLAM PHARMACEUTICALS INC EBITDA is ‪−2.60 B‬ MXN, and current EBITDA margin is −12.48%. See more stats in ALNYLAM PHARMACEUTICALS INC financial statements.
Like other stocks, ALNY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALNYLAM PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALNYLAM PHARMACEUTICALS INC technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALNYLAM PHARMACEUTICALS INC stock shows the strong buy signal. See more of ALNYLAM PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.